RNLX Renalytix Plc Stock Quote

RNLX [NASD]

Healthcare | Diagnostics & Research | United Kingdom

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	36.02M	Perf Week	-14.14%
Market Cap	748.84M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	-	Shs Float	5.91M	Perf Month	-17.98%
Income	-	PEG	-	EPS next Q	-0.12	Inst Own	16.70%	Short Float	4.75%	Perf Quarter	-38.96%
Sales	1.02M	P/S	734.87	EPS this Y	72.30%	Inst Trans	1.20%	Short Ratio	2.81	Perf Half Y	-33.15%
Book/sh	2.41	P/B	8.22	EPS next Y	5.70%	ROA	-	Target Price	38.00	Perf Year	46.67%
Cash/sh	1.97	P/C	10.05	EPS next 5Y	-	ROE	-	52W Range	9.91 - 35.71	Perf YTD	23.75%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-44.55%	Beta	-
Dividend %	-	Quick Ratio	21.20	Sales past 5Y	-	Gross Margin	-	52W Low	99.87%	ATR	2.18
Employees	17	Current Ratio	21.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.39	Volatility	9.89% 9.28%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-305.60%	Profit Margin	-	Rel Volume	1.67	Prev Close	18.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	99.74K	Price	19.80
Recom	2.50	SMA20	-17.71%	SMA50	-26.36%	SMA200	-23.27%	Volume	166,659	Change	9.94%

Jul-02-21

Initiated

Berenberg

Buy

$38

Aug-11-20

Initiated

Stifel

Buy

Sep-14-21 07:00AM	Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX Enabled Health Care Model GlobeNewswire -12.45%
Sep-09-21 06:03AM	3 High-Growth Healthcare Stocks to Buy in September Motley Fool -5.53%
Sep-03-21 07:00AM	Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference GlobeNewswire
Aug-30-21 07:00AM	Renalytix Appoints Daniel J. Levangie to its Board of Directors GlobeNewswire +11.81%
06:36AM	3 High-Growth Stocks That Could Soar by 30% or Better According to Wall Street Motley Fool
Aug-26-21 07:00AM	Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX Testing at Primary Care Level GlobeNewswire +7.36%
Aug-03-21 06:16AM	3 High-Growth Healthcare Stocks to Buy in August Motley Fool -5.04%
Jul-28-21 07:00AM	Renalytix Appoints Ann Berman to its Board of Directors GlobeNewswire +7.45%
Jul-26-21 07:00AM	Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference GlobeNewswire
Jul-22-21 07:00AM	Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory GlobeNewswire
Jul-16-21 06:19AM	3 High-Growth Stocks Truly Headed for the Moon Motley Fool
Jul-11-21 08:43AM	3 Top Life Science Stocks to Buy on Sale Right Now Motley Fool
Jun-28-21 07:00AM	KidneyIntelX Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time GlobeNewswire
Jun-15-21 07:00AM	Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 GlobeNewswire
Jun-10-21 08:00AM	Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update GlobeNewswire
Jun-07-21 07:00AM	Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment GlobeNewswire
Jun-03-21 07:00AM	Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care GlobeNewswire
Jun-02-21 11:34AM	Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order PR Newswire
11:34AM	Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order CNW Group
May-19-21 07:00AM	Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health GlobeNewswire +6.68%
May-04-21 02:20PM	Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards PR Newswire -5.98%
Apr-22-21 07:00AM	U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing GlobeNewswire +15.15%
Apr-20-21 07:21AM	Fulgent Genetics' CEO Just Told Investors To Look Out For An Acquisition Motley Fool
07:00AM	KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS) GlobeNewswire
Apr-14-21 07:00AM	RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform GlobeNewswire
Apr-08-21 07:00AM	Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions GlobeNewswire +5.18%
Apr-05-21 07:00AM	Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure GlobeNewswire
Mar-15-21 07:00AM	Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics GlobeNewswire
Mar-10-21 10:31AM	Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in the Joint Ventures Category PR Newswire
Mar-04-21 01:00PM	Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights GlobeNewswire -8.57%
Mar-02-21 07:00AM	RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 GlobeNewswire
06:30AM	Renalytix AI Plc - ADR to Host Earnings Call ACCESSWIRE
Feb-24-21 08:00AM	The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health GlobeNewswire +7.78%
Feb-23-21 02:00AM	RenalytixAI to announce Financial Results for six and three months ended December 31, 2020 GlobeNewswire -6.35%
Feb-10-21 11:31AM	FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma PR Newswire
Feb-08-21 07:30AM	Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America PR Newswire
Feb-04-21 07:00AM	American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health GlobeNewswire
Jan-13-21 02:00AM	Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics GlobeNewswire +18.77%
Jan-06-21 08:54AM	Renalytix AI (RNLX) Catches Eye: Stock Jumps 7% Zacks
07:30AM	The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga
Jan-05-21 06:00AM	Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita GlobeNewswire +6.89%
Jan-04-21 08:05AM	RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Nov-29-20 11:42AM	Do Hedge Funds Love Renalytix AI plc (RNLX)? Insider Monkey
Nov-25-20 07:30AM	Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies PR Newswire +31.71%
07:00AM	RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021 GlobeNewswire
Nov-13-20 02:00AM	RenalytixAI to Participate in the Stifel 2020 Healthcare Conference GlobeNewswire
Nov-06-20 07:00AM	Renalytix AI plc (RenalytixAI or the Company) Change of adviser GlobeNewswire
Nov-02-20 10:30AM	Posting of Annual Report & Accounts and Notice of AGM GlobeNewswire
Oct-28-20 07:30AM	EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the UK and Europe PR Newswire
Oct-27-20 03:00AM	Renalytix AI plc (RenalytixAI or the Company) Full Year Report GlobeNewswire
Oct-26-20 07:30AM	CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits PR Newswire +6.19%
Sep-22-20 07:00AM	RenalytixAI Receives California Commercial Laboratory Certification GlobeNewswire
Sep-18-20 07:00AM	RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System GlobeNewswire
Aug-26-20 07:00AM	RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX GlobeNewswire
Aug-21-20 03:00AM	RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease GlobeNewswire
Aug-03-20 08:00AM	KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients GlobeNewswire +7.33%
Jul-27-20 08:00AM	RenalytixAI Announces Over Allotment Option Exercise Raises an Additional US$10.9M GlobeNewswire +6.17%
Jul-21-20 03:57PM	RenalytixAI Announces Closing of Global Offering and Resulting Total Voting Rights GlobeNewswire
Jul-16-20 11:38PM	RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market GlobeNewswire

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience